Stockscreener 앱 받기
13.75
8.33%
-1.25
Tonix Pharmaceuticals Holding Corp 주식(TNXP)의 최신 뉴스
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment - Minichart
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget
Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - GuruFocus
Tonix doses first patient in migraine treatment study By Investing.com - Investing.com India
Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks
Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan
Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
TNXP SEC FilingsTonix Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Why (TNXP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
FY2028 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
Tonix Pharmaceuticals Holding Corp. (TNXP) Presents at BIO-Europe Spring 2026Slideshow - Seeking Alpha
TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch - Research Tree
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - The Manila Times
Tonix Pharmaceuticals Announces Upcoming Presentations on TNX-4800 and TNX-801 at World Vaccine Congress 2026 - Quiver Quantitative
Lyme disease and mpox studies put Tonix on vaccine congress agenda - Stock Titan
Levels Update: What are Tonix Pharmaceuticals Holding Corps earnings expectationsEarnings Performance Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ: TNXP) Seeks 1:2–1:250 Reverse Split; PwC Ratification - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals Holding Corp. Trade Ideas — LSX:A40VM0 - TradingView
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tonix Pharmaceuticals says prescriptions for chronic pain drug top 4,200 since launch - MSN
Tonix Pharma CEO Makes Bold Insider Move Signaling Growing Confidence - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares - MarketBeat
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - Bitget
Tonix Pharmaceuticals (TNXP) CEO adds 15,000 shares in open-market buy - Stock Titan
Tonix Pharmaceuticals Files 8-K Announcing Change in Independent Registered Public Accounting Firm - Minichart
Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings - MarketBeat
Auditor change at Tonix (NASDAQ: TNXP) after going concern warning - Stock Titan
Tonix CEO to spotlight fibromyalgia and Lyme programs in Lisbon - Stock Titan
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum (NASDAQ:TNXP) - Seeking Alpha
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’ - MSN
OTC Markets Hosts Virtual Investor Presentation with Dr. Seth Lederman, Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, and David Bautz, PhD, Senior Analyst at Zacks SCR - Yahoo Finance
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch - Sahm
Understanding Momentum Shifts in (TNXP) - Stock Traders Daily
Tonix Pharma earnings missed by $0.79, revenue topped estimates - Investing.com South Africa
Tonix Pharmaceuticals reports $13.1M product revenue, $124.0M net loss for FY2025 - TradingView
Tonix Pharmaceuticals (TNXP) Reports Mixed Q4 Results with Reven - GuruFocus
[ARS] Tonix Pharmaceuticals Holding Corp. SEC Filing - Stock Titan
Tonix Pharmaceuticals Q4 Earnings Beat Expectations with Revenue Surge - Intellectia AI
Tonix (TNXP) Sees Transformational Year with FDA Approval and St - GuruFocus
Tonix Pharmaceuticals Wins FDA Approval for TONMYA in Fibromyalgia and Expands CNS, Immunology, and Rare Disease Pipeline - Minichart
Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Quarterly Earnings Results - MarketBeat
Tonix Pharmaceuticals Holding Corp. Announces Successful Launch of TONMYA™ for Fibromyalgia and Provides 2025 Financial Highlights - Quiver Quantitative
Tonix Pharmaceuticals Holding 2025 10-K — Revenue $13.1M, EPS (14.57) - TradingView
First new fibromyalgia drug in 15 years sees 4,200 Tonmya prescriptions - Stock Titan
Aug Chart Watch: What are the future prospects of Tonix Pharmaceuticals Holding CorpTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
TNXP: New fibromyalgia drug launch shows positive uptake; Lyme prevention antibody advances in pipeline - TradingView
Tonix Pharmaceuticals Holding Corp. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Tonix presents fibromyalgia drug data at Poland conference By Investing.com - Investing.com South Africa
B2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured Conference - TradingView
TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) Approved by FDA for Fibromyalgia—Tonix Pharmaceuticals Presents Positive Phase 3 Data Showing Rapid Pain Relief and Favorable Benefit-Risk Profile - Minichart
Tonix Pharmaceuticals (TNXP) Highlights New Findings on Tonmya a - GuruFocus
Tonix Pharma Highlights Positive Phase 3 Fibromyalgia Data - TipRanks
0.04%
0.06%
자본화:
|
볼륨(24시간):